In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Incyte, with a price target of $86.00. The company’s shares closed last Wednesday at $69.59, close to its 52-week low of $69.42.
According to TipRanks.com, Abrahams is a 3-star analyst with an average return of 3.7% and a 47.3% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $97.13 average price target, a 32.8% upside from current levels. In a report released yesterday, Mizuho Securities also assigned a Hold rating to the stock with a $95.00 price target.
Jazz Pharmaceuticals (JAZZ)
In a report released today, Ami Fadia from Needham initiated coverage with a Buy rating on Jazz Pharmaceuticals and a price target of $220.00. The company’s shares closed last Wednesday at $129.55, close to its 52-week low of $127.80.
According to TipRanks.com, Fadia is a 1-star analyst with an average return of -0.4% and a 43.8% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and Avadel Pharmaceuticals.
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $213.63.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.